Compare RBBN & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | KMDA |
|---|---|---|
| Founded | 1997 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.4M | 460.3M |
| IPO Year | 2017 | 2013 |
| Metric | RBBN | KMDA |
|---|---|---|
| Price | $3.07 | $7.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.67 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.0M | 50.3K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | ★ 170.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.97 | $13.94 |
| Revenue Next Year | $6.69 | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $6.50 |
| 52 Week High | $4.29 | $9.35 |
| Indicator | RBBN | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 65.72 | 40.27 |
| Support Level | $2.72 | $7.66 |
| Resistance Level | $3.09 | $8.55 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 75.60 | 34.10 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.